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Summary We have previously reported an apparently paradoxical association
between medical care related factors and an increased risk of chronic obstructive
pulmonary disease (COPD) re-hospitalisation, in a cohort of 346 COPD subjects from
Barcelona, Spain. Confounding by severity or by indication is a plausible explanation.
We tested the confounding effect of severity-related variables on these paradoxical
associations. Forced expiratory volume in one second (FEV1), arterial oxygen
pressure (PO2) and previous COPD admissions were associated with: (1) the presence
of medical care related factors, and (2) re-admission during follow-up. Risks of re-
admission associated with most of the medical care related factors were reduced
after adjustment for the severity variables. The risk associated with long-term
oxygen therapy use changed from a crude OR of 2.36 (95% CI: 1.79–3.11) to an
adjusted OR of 1.38 (0.95–2.00), while that associated with anticholinergics use
varied from 3.52 (2.37–5.21) to 2.10 (1.32–3.36)). We concluded that the excess risk
of COPD re-admission associated with medical care related factors might be partially
due to confounding by indication. Residual confounding may still account for part of
the remaining excess risk. True adverse effects of some pharmacological treatments
cannot be excluded.







*Corresponding author. Tel.: þ 34-93-2211009; fax: þ 34-93-2213237.









Aguditzaci !o de la
%
MPOC (Risk Factors of COPD Exacerbation Study). The EFRAM investigators
are: Josep M Ant!o (Principal Investigator), Judith Garcia-Aymerich and Jordi Sunyer from the Respiratory and Environmental Health
Research Unit, IMIM, Barcelona; Jordi Alonso from the Health Services Research Unit, IMIM, Barcelona; Esther Barreiro and Miquel A
F !elez from the Department of Pneumology, Hospital del Mar, Barcelona; Joan Escarrabill, Eva Farrero and Ma Jos!e Redondo from the
Department of Pneumology, Ciutat Sanit"aria i Universit"aria de Bellvitge, L’Hospitalet de Llobregat; Ramon M Marrades, N!estor Soler
and Antoni Torres from the Department of Pneumology, Hospital Cl!ınic i Provincial de Barcelona, Barcelona; Gl"oria Bonet, Jos !e
Izquierdo, Eduard Mons !o and Josep Morera from the Department of Pneumology, Hospital Germans Trias i Pujol, Badalona.
0954-6111/$ - see front matter & 2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.rmed.2004.02.019
Respiratory Medicine (2004) 98, 851–857
Introduction
Several studies on the course of chronic obstructive
pulmonary disease (COPD) and its determinants
have found paradoxical or unexpected results.
Smoking cessation has been independently
related to an increased risk of COPD re-admission,1
a lack of reduction in overall mortality2 and
even to an increase of respiratory mortality3 in
COPD patients. Schols et al.4 found that in
severe COPD, maintenance treatment with sys-
temic glucocorticoids was related to an increased
mortality in a dose-dependent manner, indepen-
dently of sex, age, body mass index, forced
expiratory volume in 1 s (FEV1), arterial oxygen
pressure (PO2), and use of inhaled corticosteroids.
Some medical care related factors, such as
being controlled by a pulmonologist, taking antic-
holinergics, taking oral corticosteroids, influenza
vaccination, respiratory rehabilitation and long-
term oxygen therapy, were related to an in-
creased risk of COPD re-admission, contrary to
the authors’ expectations andFin some casesFto
the previous literature, in the follow-up of 340
COPD patients included in the study of the risk
factors of COPD exacerbation (EFRAM study).5
This association between medical care related
factors and COPD re-admission had also been found
in the previous case–control EFRAM study,1
although it was more evident in the follow-up
analysis.
As all unexpected findings alluded to above
have been found in observational studies, it is
likely that they can be partly attributed to the
lack of randomisation of factors that affect the
outcome under study. Anthonisen explained para-
doxical results regarding smoking cessation as a
situation of self-selection bias, in which patients
who are severely ill spontaneously quit smoking
in response to their symptoms and disability and
do not do well afterwards.6 The increased mortality
associated with glucocorticoids use was attri-
buted by Schols et al.4 to a confounder by
indication, such as frequent disease exacerbations.
Surprisingly, so far no formal analysis has been
focused on the identification and control of
potential confounders in observational studies on
the course of COPD.
In the present analysis, we aimed to test the
confounding effect of FEV1, PO2 and previous COPD
admissions in the reported association between
medical care related factors (being controlled by a
pulmonologist, taking anticholinergics, taking oral
corticosteroids, influenza vaccination, respiratory




A systematic sample of 1 out of every 2 patients
hospitalised or remaining in the emergency room
for at least 18 h for a COPD exacerbation (index-
admission) in four tertiary hospitals in the Barce-
lona area over 1 year (from May 1, 1997 to April 30,
1998) was identified. A total of 404 episodes of
admission corresponding to 346 patients were
obtained. In patients with more than one admission
during the recruitment period, the first one was
selected as the beginning of the follow-up period.
COPD diagnosis was established by the ward
pulmonologist and based on medical history, cur-
rent symptoms and available pulmonary function
tests, following the ERS guidelines.7 An exacerba-
tion was defined when the patient reported an
increase in dyspnea, in sputum production or
sputum purulence.8 Recruitment methods and
diagnosis criteria have been detailed in previous
papers.1,9
Information about potential risk factors was
collected at baseline, including clinical status,
medical care and prescriptions, medication adher-
ence, lifestyle, quality of life and social support.
Medical care related factors included: being con-
trolled by a pulmonologist or by the general
practitioner, taking anticholinergics, taking oral
corticosteroids, influenza vaccination, respiratory
rehabilitation and long-term oxygen therapy. COPD
admissions in the previous year were reported by
the patient and taken from the clinical records.
Lung function and blood gases were measured at
least 3 months after admission and during a period
of clinical stability. Three hundred and forty
patients were followed for a mean period of 1.1
years and information on further hospitalisations
was obtained.5 The Ethics Committees of the
participating hospitals approved the protocol and
written informed consent was obtained from all
patients.
Statistical analysis
The term confounding refers to a situation in which
a non-causal association between a given exposure
and an outcome is observed as a result of the
influence of a third variable (or group of vari-
ables).10 Residual confounding may occur when the
control for confounders is incomplete or when some
confounding variables remain unaccounted for. In
order to assess confounding, we followed the
strategy suggested by Szklo and Nieto.10
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First, the association between a confounding
variable (FEV1, PO2 or previous COPD admissions)
and the exposure (medical care related factors)
was assessed. Thus, we estimated the prevalence
at index-admission of medical care related factors
stratified by FEV1, PO2, and previous COPD admis-
sions. Second, the association of the confounding
variable (FEV1, PO2 or previous admissions) with the
outcome (COPD re-admission) was estimated using
time from recruitment (index-admission) to first
event (following COPD re-admission) as the out-
come variable in a Cox proportional hazards
model,11 as has been reported elsewhere.5 Finally,
we assessed the associations, both crude and
adjusted for FEV1, PO2 and previous admissions,
between medical care related factors and COPD re-
admission using Cox regression, looking for changes
in direction and magnitude of the association.
Percent excess risk explained by the confounders
was computed as: ‘‘((unadjusted HR-adjusted HR)/
(unadjusted HR-1.00))*100’’.10 Age and hospital of
recruitment were tested as possible effect modi-
fiers of the association between medical care
related factors and COPD re-admission using stra-
tification in the Cox regression. All analyses were
performed with Stata, release 6.0 (StataCorp,
1999, College Station, TX, USA).
Results
First, the association between the confounding
variable (FEV1, PO2 or previous COPD admissions)
and the exposure (medical care related factors)
was assessed by estimating the prevalence at
index-admission of medical care related factors
stratified by FEV1, PO2, and previous COPD admis-
sions. Table 1 shows that the age-adjusted pre-
valence of most medical care related factors
(control by the pulmonologist, anticholinergics
intake, oral corticosteroids intake, respiratory
rehabilitation, and long-term oxygen therapy
(LTOT)) was higher in patients with lower levels of
FEV1. For control by the pulmonologist, antic-
holinergics use and LTOT, such differences in
prevalence showed a dose–response pattern, and
were statistically significant. After stratifying by
PO2 levels, differences in the prevalence of being
controlled by the pulmonologist and LTOT use were
found, the latter being statistically significant
(Table 1). At recruitment, 81% of patients had had
some previous COPD admission. These patients
showed a higher prevalence of all medical care
related factors than those who had never had a
COPD admission, some of the differences being
statistically significant (Table 2). After stratifica-
tion for number of COPD admissions in the year
prior to recruitment, a dose–response pattern
was only found for anticholinergics use and LTOT
(Table 2).
The positive association of medical care related
factors with further COPD admission partially
reduced its magnitude and significance after
adjustment by FEV1, PO2 or previous COPD admis-
sions, and accordingly the percent excess risk
explained by the confounders was high, with the
exception of oral corticosteroids use and influenza
vaccination (Table 3). Regarding previous admis-
sions, results were very similar independently
of whether it was included as a continuous or
categoricalFwith different cut-off pointsF
variable (e.g., HR for LTOT use after adjustment
by FEV1, PO2 and continuous previous admissions,
1.23 (0.84–1.81); HR for LTOT use after adjustment
by FEV1, PO2 and categorised previous admissions
(o3 or X3), 1.38 (0.94–2.00); all results available
from the authors). There were no substantial
differences in the above-mentioned associations
after stratification by age groups or by hospital of
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Table 1 At recruitment age adjusted prevalence (in percentage) and 95% confidence interval of medical care
related factors among patients admitted for a COPD exacerbation, according to FEV1 ATS
n stages and PO2 levels.
Factors at recruitment
(index-admission)
FEV1 ATS stages PO2 levels
FEV1X50% FEV1¼ 35–49% FEV1o35% PO2460mm Hg PO2p60mm Hg
n ¼ 42 (14%) n ¼ 71 (25%) n ¼ 176 (61%) n ¼ 156 (60%) n ¼ 102 (40%)
Controlled by pulmonologist 41 (27–56) 56 (44–67) 66 (58–72) 57 (49–64) 72 (63–80)
Anticholinergics 55 (40–69) 73 (62–82) 82 (76–87) 75 (68–81) 79 (71–86)
Oral corticosteroids 12 (5–26) 27 (18–38) 23 (17–29) 23 (17–30) 22 (15–32)
Influenza vaccination 69 (54–81) 75 (63–84) 71 (64–77) 79 (72–85) 69 (59–77)
Respiratory rehabilitation 5 (1–17) 10 (5–19) 15 (10–21) 11 (7–17) 13 (8–21)
Long-term oxygen therapy 21 (12–36) 23 (14–34) 40 (33–47) 17 (12–24) 62 (52–71)
nATS: American Thoracic Society.








STable 3 Change in the association between medical care related factors and admission for a COPD exacerbation after adjustment by severity and previous
admissions in a cohort of COPD patients.
Crude HR (95% CI) Adjusted HR (95% CI) Adjusted HR (95% CI) Adjusted HR (95% CI) Adjusted HR (95% CI) % excess riskn
by FEV1 by PO2 by previous admissions by FEV1, PO2 and explained by
previous admission FEV1, PO2 and
previous admissions
Controlled by pulmonologist 2.16 (1.43–3.27) 2.11 (1.33–3.33) 1.76 (1.10–2.83) 2.03 (1.33–3.33) 1.73 (1.05–2.85) 37%
Anticholinergics 3.52 (2.37–5.21) 2.62 (1.69–4.05) 2.74 (1.76–4.28) 3.08 (2.06–4.60) 2.10 (1.32–3.36) 56%
Oral corticosteroids 1.55 (1.13–2.11) 1.47 (1.05–2.04) 1.71 (1.21–2.41) 1.40 (1.03–1.92) 1.71 (1.19–2.44) Fw
Influenza vaccination 1.37 (1.01–1.87) 1.26 (0.90–1.75) 1.27 (0.89–1.82) 1.29 (0.95–1.76) 1.35 (0.93–1.94) 6%
Respiratory rehabilitation 1.77 (1.23–2.57) 1.38 (0.92–2.08) 1.58 (1.03–2.42) 1.63 (1.12–2.37) 1.28 (0.83–2.00) 64%
Long-term oxygen therapy 2.36 (1.79–3.11) 1.91 (1.40–2.60) 1.62 (1.14–2.31) 2.00 (1.49–2.69) 1.38 (0.95–2.00) 72%
HR: hazard ratio; CI: confidence interval. Each line is a single model.
nPercent excess risk explained by the variables adjusted for is computed as: ((unadjusted HR-adjusted HR)/(unadjusted HR-1.00))*100 (reference 10).
wNot applicable.
Table 2 At recruitment age adjusted prevalence (in percentage) and 95% confidence interval of medical care related factors among patients admitted for a COPD
exacerbation, according to previous COPD admissions.
Factors at recruitment
(index-admission)
COPD admissions ever COPD admissions in the year prior to recruitment
No Yes P 0 1 2 3 43
n ¼ 67 (19%) n ¼ 279 (81%) n ¼ 145 (42%) n ¼ 66 (19%) n ¼ 52 (15%) n ¼ 39 (11%) n ¼ 44 (13%)
Controlled by pulmonologist 28 (19–40) 63 (57–69) o0.0001 40 (33–49) 77 (66–86) 66 (52–77) 65 (49–79) 59 (45–73)
Anticholinergics 43 (32–55) 82 (77–86) o0.0001 54 (46–62) 82 (71–89) 90 (79–96) 92 (78–97) 96 (84–99)
Oral corticosteroids 13 (7–24) 23 (18–28) 0.082 12 (7–18) 26 (17–37) 27 (17–41) 23 (12–38) 37 (24–52)
Influenza vaccination 64 (52–75) 73 (68–78) 0.138 66 (58–73) 80 (68–88) 71 (57–82) 76 (60–87) 72 (57–84)
Respiratory rehabilitation 6 (2–14) 14 (11–19) 0.060 5 (2–10) 16 (9–27) 19 (11–32) 10 (4–23) 28 (16–43)












recruitment, thus excluding a possible role of
effect modifier by age or hospital (results available
from the authors).
Discussion
The present finding of significant associations
between medical care related factors and a group
of severity factors (FEV1, PO2 and previous admis-
sions), together with the previously reported
associations between these particular severity
factors and COPD re-admission,1,5 suggest that
FEV1, PO2 and previous admissions may be con-
founders of the previously reported 5 associations
between medical care related factors and COPD re-
admission. The fact that these associations were
substantially reduced after adjusting for the
severity related variables alluded to above, and
the homogeneity of the pattern of confounding for
a large number of medical care related factors,
strongly suggest the presence of confounding by
severity or by indication.12 Although the mechan-
ism of confounding is usually not directly observa-
ble, the bi-directional nature of our study allowed
us to elucidate it. Such mechanism is clear with the
experience of 22 patients that at recruitment
(index-admission) showed PO2p55mm Hg and were
not using LTOT. As a consequence of the index-
admission, two-thirds of them were prescribed
LTOT. Since PO2 is a relevant variable for the
indication of LTOT in a COPD patient, it was not
surprising that in our data the association between
LTOT and COPD re-admission changed from an
unadjusted OR of 2.36 (1.79–3.11) to an OR of
1.62 (1.14–2.31) after adjustment for PO2 and to
1.38 (95% IC: 0.95–2.00) after further adjustment
for FEV1 and previous admissions.
The fact that even after adjustment for FEV1,
PO2 and previous admissions some medical care
related factors were still associated to COPD re-
admission was not surprising since residual con-
founding is easy to remain.10 Possible explanations
for residual confounding in our study are: the
existence of other confounders in the association
between medical care related factors and COPD re-
admission, measurement error in questionnaires
and lung function testing, and the lack of informa-
tion on longitudinal changes of the relevant
variables.13 Pulmonary hypertension is one of the
possible co-confounders, because patients suffer-
ing it have a higher risk of COPD re-admission14 and
probably have a higher proportion of medical care
related factors.15 Similar associations could be
speculated for chronic mucus hypersecretion16 or
muscular weakness.17 Unfortunately neither these
factorsFnor proxy measures of themFwere mea-
sured in our study. Other non-respiratory comorbid-
ities such as cardiac disease could also be co-
confounders by indication, because they can direct
or indirectly modify both the physician control or
prescriptions, and the risk of COPD admission. In
our study, the analysis of the confounding effect of
a list of self-reported chronic comorbid conditions
did not show a confounder pattern for ‘‘having at
least one comorbidity’’ nor for ‘‘cardiac comorbid-
ity’’, although misclassification due to self-report-
ing cannot be discarded. In the present study we
performed classical confounding analysis, but sev-
eral alternative designs and analytical strategies
have been proposed to deal with time-dependent
variables, and specifically to avoid confounding by
indication. Thus, case-crossover 18 and case–time–
control 19 designs, as well as G-estimation 20 and
marginal structural 21 models should be considered
for future studies in COPD patients. Because
confounding by indication may be related to
specific hospitals within the same study, multilevel
analysis including hospital as an ecological treat-
ment variable has been proposed to reduce
confounding,22 although this approach would re-
quire the inclusion of about 50 groups (hospitals).23
We have previously reported differences in the risk
of COPD re-admission between the hospitals in-
volved in our study although these differences were
removed after adjustment for type of physician and
use of anticholinergics.5
Previous studies have also found unexpected
associations between medical care related factors
and COPD outcomes. Treatment with anticholiner-
gics (ipratropium) was independently associated
with an increased risk of death from asthma and
COPD in a large cohort of asthmatic patients.24 The
authors attributed these results to the lack of
information about coexisting COPD, which could be
acting as a confounder by indication. However, they
also suggested that the difficulty to expectorate
due to the drying effect of ipratropium on lung
secretions, and the development of tachycardia,
are possible mechanisms for a causal relationship. A
subsequent large database study of elderly asth-
matic and COPD patients was unable to reproduce
these results.25 In the 5-year follow-up of the Lung
Health Study, a randomised clinical trial involving
5887 smokers aged 35–60, there was a tendency for
coronary and cardiovascular disease morbidity to
be more common among smoking-intervention-
ipratropium participants than smoking-interven-
tion-placebo participants, which was attributed
to side-effects of ipratropium bromide.26
Another study found an increased mortality in
ARTICLE IN PRESS
Confounding by indication in COPD 855
severe COPD patients independently related to oral
corticosteroids.4 The authors suggested that pre-
vious admissionsFa factor not measuredFcould
be acting as a confounder by indication, although
the association could also be due to the side-effects
of sustained use of systemic corticoids, mainly
myopathy and immunosuppressive effects.4 In our
study, none of the severity variables accounted for
any part of the excess risk of re-admission among
oral corticosteroids users, as is shown in Table 3,
pointing to the ‘‘side-effects explanation’’ rather
than to the ‘‘confounding explanation’’. The inter-
pretation of unexpected findings is more difficult in
the case of pharmacological treatments than in the
remaining medical care related factors, because
true adverse effects are frequently a plausible
explanation, and which can even coexist with
confounding. In our study, the inclusion of a wide
range of potential risk factors of COPD exacerba-
tion1 allowed us to find that several paradoxical
associations were clustered in the same group of
medical care related factors, suggesting a single
common explanation. Further observational studies
on COPD outcomes should include a variety of
medical care related factors to better understand
the paradoxical associations if present, although
adverse drug side-effects must always be consid-
ered for the sake of the patients.
In conclusion, the present study supports the
hypothesis that the excess risk of COPD re-admis-
sion associated with medical care related factors
might be partially due to confounding by indica-
tion. Residual confounding may still account for
part of the remaining excess risk. True adverse
effects of some pharmacological treatments cannot
be excluded. Moreover, our results show that the
magnitude of the confounding effect of FEV1, PO2
and previous COPD admissions can be large, and so
the lack of adjustment for such factors, even when
the crude association between the exposure and
the outcome is large (e.g., relative risk higher than
two and statistically significant) may lead to biased
estimates. Both conclusions strongly suggest that
further studies on COPD prognosis should include a
broader characterisation of patients, not only
based on lung function impairment.4 In addition,
patients should be recruited at a similar point in
the course of the disease, according to recommen-
dations of Evidence-Based Medicine for studies of
prognosis.27
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